944892-25-5 Usage
General Description
2-butyl-1,3,4-oxadiazole is a chemical compound with the molecular formula C6H11N3O. It belongs to the oxadiazole family of compounds and is characterized by a five-membered ring containing one oxygen atom and two nitrogen atoms. 2-butyl-1,3,4-oxadiazole is a colorless liquid with a faint odor and is insoluble in water. It is mainly used as a chemical intermediate in the production of pharmaceuticals, agrochemicals, and other organic compounds. 2-butyl-1,3,4-oxadiazole has also been studied for its potential biological and pharmacological activities, including antimicrobial, antiviral, and antitumor properties. However, further research is needed to fully understand the potential applications and effects of 2-butyl-1,3,4-oxadiazole.
Check Digit Verification of cas no
The CAS Registry Mumber 944892-25-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,4,4,8,9 and 2 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 944892-25:
(8*9)+(7*4)+(6*4)+(5*8)+(4*9)+(3*2)+(2*2)+(1*5)=215
215 % 10 = 5
So 944892-25-5 is a valid CAS Registry Number.
InChI:InChI=1/C6H10N2O/c1-2-3-4-6-8-7-5-9-6/h5H,2-4H2,1H3
944892-25-5Relevant articles and documents
Development of orally active nonpeptidic inhibitors of human neutrophil elastase
Ohmoto,Yamamoto,Okuma,Horiuchi,Imanishi,Odagaki,Kawabata,Sekioka,Hirota,Matsuoka,Nakai,Toda,Cheronis,Spruce,Gyorkos,Wieczorek
, p. 1268 - 1285 (2007/10/03)
5-Amino-2-phenylpyrimidin-6-ones, some of their desamino derivatives, and miscellaneous derivatives were synthesized and biologically evaluated on both in vitro activity and oral activity in an acute hemorrhagic assay. These compounds contained an α-keto-1,3,4-oxadiazole moiety to bind covalently to the Ser-195 hydroxy group of human neutrophil elastase (HNE). Among those tested, compounds 11a-c,e,i-l(F), 11d,e,k(H), 21d,e,k(F), and 21d,e(H) showed a good oral profile. RS-Mixture 3(H) was selected for clinical evaluation based on its oral potency, duration of action, enzyme selectivity, safety profile, and ease of synthesis. Structure -activity relationships (SARs) are discussed.
